Management Team

Holli joined Ampio Pharmaceuticals in 2013, and prior to taking her current role, she served as the company’s vice president of operations and oversaw clinical, regulatory and manufacturing operations. She has held roles of increasing responsibility throughout her career including site leadership, strategic planning, contractor management, and product portfolio leadership.

Previously, Holli was the Director of Business Development at the American College of Radiology (ACR) Image Metrix. Holli earned a Bachelor of Arts from California State University, Chico, and holds a Master’s of Science in Biomedical and Molecular Sciences Research from King’s College, London.

Holli is a member of the Parenteral Drug Association, Colorado Bioscience Association and the International Society of Pharmaceutical Engineers, and has represented Ampio Pharmaceuticals at conferences for the International Society of Pharmaceutical Engineers as well as at Global Investment Conferences.

Daniel G. Stokely has more than 30 years of experience in finance and accounting. Daniel began his career at Deloitte & Touche and since that time, he has spent the majority of his career in positions of financial leadership within both publicly traded and privately-held pharmaceutical companies. Most recently, since 2012, Daniel served as Executive Vice President and Chief Financial Officer of Sentynl Therapeutics Inc., a privately-held specialty pharmaceutical company focused on in-licensing, acquisition, marketing and distribution of development stage and commercially marketed prescription pain products, which was sold to Cadila Healthcare Ltd. in January 2017. From 2004 to 2012, Daniel served as Vice President of Finance and Chief Accounting Officer of Victory Pharma, a privately-held specialty pharmaceutical company focused on in-licensing, internal product development, marketing and distribution of pain specialty products, which was sold to Shionogi, Inc., a Japanese pharmaceutical company, in 2011. From 2001 to 2004, Daniel served as the Corporate Controller and Chief Accounting Officer for Wireless Facilities, Inc. (currently Kratos Defense & Security Solutions), a publicly traded, global provider of communications and security services for the wireless communications industry. From 1994 to 2001, Daniel served as Corporate Controller of Dura Pharmaceuticals, a publicly traded pharmaceutical company that was sold to Elan Pharmaceuticals in late 2000. Daniel has a bachelor’s degree in accounting from San Diego State University and is a Certified Public Accountant (licensed in California).